NEW YORK (GenomeWeb News) – Sanford-Burnham Medical Research Institute and Intrexon have struck a collaboration focused on developing new induced pluripotent stem cell technologies for research purposes, the institute said today.

Under the plan, Sanford-Burnham researchers will use Intrexon's RheoSwitch Therapeutic System (RTS) and its Laser-Enabled Analysis and Processing (LEAP) instrument for cellular selection and gene regulation purposes. Intrexon may obtain commercial and intellectual property rights to technologies that result from the partnership, Sanford-Burnham said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.